AU2016324920B2 - Dactinomycin compositions and methods for the treatment of acute myeloid leukemia - Google Patents
Dactinomycin compositions and methods for the treatment of acute myeloid leukemia Download PDFInfo
- Publication number
- AU2016324920B2 AU2016324920B2 AU2016324920A AU2016324920A AU2016324920B2 AU 2016324920 B2 AU2016324920 B2 AU 2016324920B2 AU 2016324920 A AU2016324920 A AU 2016324920A AU 2016324920 A AU2016324920 A AU 2016324920A AU 2016324920 B2 AU2016324920 B2 AU 2016324920B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- administered
- subject
- dactinomycin
- disclosure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562218433P | 2015-09-14 | 2015-09-14 | |
US62/218,433 | 2015-09-14 | ||
PCT/EP2016/071599 WO2017046108A1 (en) | 2015-09-14 | 2016-09-13 | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2016324920A1 AU2016324920A1 (en) | 2018-04-05 |
AU2016324920B2 true AU2016324920B2 (en) | 2022-03-03 |
Family
ID=56896582
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2016324920A Active AU2016324920B2 (en) | 2015-09-14 | 2016-09-13 | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
Country Status (7)
Country | Link |
---|---|
US (2) | US10335416B2 (es) |
EP (1) | EP3349759B1 (es) |
JP (1) | JP7001599B2 (es) |
AU (1) | AU2016324920B2 (es) |
CA (1) | CA2998042C (es) |
ES (1) | ES2809805T3 (es) |
WO (1) | WO2017046108A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2998042C (en) | 2015-09-14 | 2022-07-05 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
EP3512560A4 (en) | 2016-09-13 | 2020-05-27 | Rasna Research Inc. | DACTINOMYCIN COMPOSITIONS AND METHODS FOR TREATING MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA |
WO2018175746A1 (en) | 2017-03-24 | 2018-09-27 | Kura Oncology, Inc. | Methods for treating hematological malignancies and ewing's sarcoma |
WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
KR20230128629A (ko) * | 2022-02-28 | 2023-09-05 | 한국유나이티드제약 주식회사 | 향상된 용해도를 가지는 닥티노마이신 함유 약학조성물의 제조방법 |
CN116942834B (zh) * | 2023-06-12 | 2024-04-05 | 新乡医学院 | 包含核仁应激诱导剂的抗肿瘤药物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060111358A1 (en) * | 2002-10-08 | 2006-05-25 | De Bont Eveline S | Treatment of aml |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US20070010466A1 (en) * | 2005-07-06 | 2007-01-11 | Branimir Sikic | Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer |
EP2397149A1 (en) | 2010-06-17 | 2011-12-21 | Hil-Invent Ges.M.B.H. | Pharmaceutical preparation comprising actinomycin D for the treatment of B-CLL in patients having del(17p) |
ES2685619T3 (es) | 2013-12-30 | 2018-10-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combinación de un compuesto de arsénico y al menos un retinoide para tratar la leucemia mielógena aguda |
CA2998042C (en) | 2015-09-14 | 2022-07-05 | Brunangelo Falini | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia |
-
2016
- 2016-09-13 CA CA2998042A patent/CA2998042C/en active Active
- 2016-09-13 EP EP16763556.4A patent/EP3349759B1/en active Active
- 2016-09-13 AU AU2016324920A patent/AU2016324920B2/en active Active
- 2016-09-13 JP JP2018532812A patent/JP7001599B2/ja active Active
- 2016-09-13 WO PCT/EP2016/071599 patent/WO2017046108A1/en active Application Filing
- 2016-09-13 US US15/759,442 patent/US10335416B2/en active Active
- 2016-09-13 ES ES16763556T patent/ES2809805T3/es active Active
-
2019
- 2019-05-21 US US16/418,374 patent/US11337983B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060111358A1 (en) * | 2002-10-08 | 2006-05-25 | De Bont Eveline S | Treatment of aml |
Also Published As
Publication number | Publication date |
---|---|
US20180207168A1 (en) | 2018-07-26 |
US10335416B2 (en) | 2019-07-02 |
ES2809805T3 (es) | 2021-03-05 |
AU2016324920A1 (en) | 2018-04-05 |
CA2998042A1 (en) | 2017-03-23 |
US20190314380A1 (en) | 2019-10-17 |
EP3349759A1 (en) | 2018-07-25 |
JP2018526460A (ja) | 2018-09-13 |
WO2017046108A1 (en) | 2017-03-23 |
EP3349759B1 (en) | 2020-05-20 |
US11337983B2 (en) | 2022-05-24 |
CA2998042C (en) | 2022-07-05 |
JP7001599B2 (ja) | 2022-01-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11337983B2 (en) | Dactinomycin compositions and methods for the treatment of acute myeloid leukemia | |
US11918558B2 (en) | Tinostamustine for use in the treatment of T-cell prolymphocytic leukaemia | |
US6632798B2 (en) | Methods for inhibiting angiogenesis | |
AU2002311985A1 (en) | Methods for inhibiting angiogenesis | |
WO2019126739A1 (en) | Pyrvinium pamoate anti-cancer therapies | |
WO2019109074A1 (en) | Mebendazole cancer therapies and methods of use | |
KR20180011210A (ko) | B―세포 악성종양의 치료를 위한 세르둘라티닙 | |
KR20200096781A (ko) | 말초 t-세포 림프종 및 피부 t-세포 림프종을 치료하기 위한 조성물 및 방법 | |
US20220323433A2 (en) | Clinical regimen for treating myelodysplastic syndrome with phosphatase inhibitor | |
EP4252754A1 (en) | Pharmaceutical composition for enhancing cell killing, and use thereof | |
US20210369699A1 (en) | Treatment of lupus erythematosus using s-hydroxychloroquine | |
US20130338232A1 (en) | Method of reducing brain cell damage, inflammation or death | |
WO2015054612A1 (en) | Treating organ-specific t cell mediated autoimmune diseases | |
US20040048808A1 (en) | Methods for inhibiting angiogenesis | |
US10639382B2 (en) | Method for treating leukemia | |
US20240025959A1 (en) | Beclin 2 and uses thereof for treating cancer and neurodegenerative diseases | |
ZA200409558B (en) | Method for the protection of endothelial and epithelial cells during chemotherapy. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |